A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
NCT06079723 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2023-10-12
Summary
Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption.
The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.
Conditions
Sponsors & Collaborators
-
Power Life Sciences Inc.
lead INDUSTRY
Principal Investigators
-
Michael B Gill · Power Life Sciences Inc.
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-30
- Primary Completion
- 2025-11-30
- Completion
- 2026-11-30
Countries
- United States
Study Locations
More Related Trials
-
Discovering Patterns in Experiences of Patients in Esophageal Cancer Clinical Research
NCT05831150 ·Status: NOT_YET_RECRUITING
-
Expanded Access of Cabozantinib in Medullary Thyroid Cancer
NCT01683110 ·Status: APPROVED_FOR_MARKETING
-
Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer
NCT03120572 ·Status: COMPLETED
-
Minimally Residual of Esophageal Cancer 001
NCT05952661 ·Status: RECRUITING
-
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06703047 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
NCT01089803 ·Status: COMPLETED
-
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
NCT00012168 ·Status: COMPLETED ·Phase: NA
-
A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma
NCT02570893 ·Status: UNKNOWN ·Phase: PHASE3
-
Biomarkers and Functional Imaging in Predicting Response of Esophageal Cancer
NCT03029793 ·Status: UNKNOWN
-
Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)
NCT01393483 ·Status: COMPLETED
-
Docetaxel and S-1 for Advanced Esophageal Cancer
NCT01693432 ·Status: UNKNOWN ·Phase: PHASE2
-
Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer
NCT02128243 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
NCT04046575 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
NCT06530316 ·Status: RECRUITING
-
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study
NCT05028231 ·Status: UNKNOWN
-
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06010303 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
NCT00784303 ·Status: COMPLETED ·Phase: PHASE2
-
Incidence of 107 Lymph Node Metastasis
NCT07165184 ·Status: RECRUITING
-
Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma
NCT03904927 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
NCT01715233 ·Status: COMPLETED ·Phase: PHASE2
-
Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma(EC-CRT-003)
NCT05512520 ·Status: RECRUITING ·Phase: PHASE2
-
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
NCT01691625 ·Status: COMPLETED ·Phase: NA
-
A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC
NCT02721563 ·Status: COMPLETED ·Phase: PHASE4
-
Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery
NCT07046221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2